PE20160950A1 - Biomarcadores de cancer y usos de los mismos - Google Patents

Biomarcadores de cancer y usos de los mismos

Info

Publication number
PE20160950A1
PE20160950A1 PE2016000450A PE2016000450A PE20160950A1 PE 20160950 A1 PE20160950 A1 PE 20160950A1 PE 2016000450 A PE2016000450 A PE 2016000450A PE 2016000450 A PE2016000450 A PE 2016000450A PE 20160950 A1 PE20160950 A1 PE 20160950A1
Authority
PE
Peru
Prior art keywords
her2
specific
union
specific binding
seq
Prior art date
Application number
PE2016000450A
Other languages
English (en)
Inventor
Sarah Batey
Haijun Sun
Robert Ely Rowland
Kinmei Leung
Original Assignee
F-Star Biotechnology Ltd
F-Star Biotechnologische Forschungs- Und Entw M B H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F-Star Biotechnology Ltd, F-Star Biotechnologische Forschungs- Und Entw M B H filed Critical F-Star Biotechnology Ltd
Publication of PE20160950A1 publication Critical patent/PE20160950A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se refiere a un miembro de union especifica que se une al Receptor 2 del Factor de Crecimiento Epidermico Humano (HER2), donde dicho miembro es: a) un miembro de union especifica que comprende un sitio de union a antigeno de HER2 modificado por ingenieria genetica en una region de bucle estructural de un dominio CH3 del miembro de union especifica y que contiene las secuencias de aminoacidos FFTYW (SEQ ID NO: 12) y DRRRWTA (SEQ ID NO:14); o b) un miembro de union especifica que compite con un miembro de union especifica de acuerdo con (a) por la union HER2. Dicho miembro es util en el metodo de tratamiento de cancer donde se tiene un numero medio de copias del gen HER2 superior o igual a 10 por celula tumoral
PE2016000450A 2013-10-04 2014-10-03 Biomarcadores de cancer y usos de los mismos PE20160950A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1317622.7A GB201317622D0 (en) 2013-10-04 2013-10-04 Cancer biomarkers and uses thereof

Publications (1)

Publication Number Publication Date
PE20160950A1 true PE20160950A1 (es) 2016-10-02

Family

ID=49630223

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000450A PE20160950A1 (es) 2013-10-04 2014-10-03 Biomarcadores de cancer y usos de los mismos

Country Status (21)

Country Link
US (1) US20160289336A1 (es)
EP (1) EP3052647B1 (es)
JP (1) JP6449308B2 (es)
KR (1) KR20160092992A (es)
CN (1) CN105722997A (es)
AU (1) AU2014330942A1 (es)
BR (1) BR112016007348A2 (es)
CA (1) CA2925186A1 (es)
CL (1) CL2016000777A1 (es)
DK (1) DK3052647T3 (es)
EA (1) EA201690450A1 (es)
ES (1) ES2687783T3 (es)
GB (1) GB201317622D0 (es)
HK (1) HK1221746A1 (es)
HR (1) HRP20181566T1 (es)
IL (1) IL244510A0 (es)
LT (1) LT3052647T (es)
MX (1) MX2016004286A (es)
PE (1) PE20160950A1 (es)
SG (1) SG11201602605TA (es)
WO (1) WO2015049537A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4937138B2 (ja) 2005-01-05 2012-05-23 エフ−シュタール・ビオテヒノロギシェ・フォルシュングス−ウント・エントヴィックルングスゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 相補性決定領域とは異なる分子の領域に設計された結合性を持つ合成免疫グロブリンドメイン
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
ES2975748T3 (es) 2007-06-26 2024-07-12 F Star Therapeutics Ltd Presentación de agentes de unión
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2016162505A1 (en) * 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN116640214A (zh) 2016-08-09 2023-08-25 科马布有限公司 分离抗体及其应用
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
CN107868814A (zh) * 2017-12-19 2018-04-03 威海威仕泰医疗科技有限公司 一种用于检测HER2基因的Dig标记探针的制备方法
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
MX2020010204A (es) * 2018-04-02 2021-01-29 Bristol Myers Squibb Co Anticuerpos anti-trem-1 y usos de los mismos.
JP2021524283A (ja) * 2018-05-17 2021-09-13 イムノーム、インコーポレイテッド Ｃｈ３ドメインエピトープタグ
CN108875302B (zh) * 2018-06-22 2022-02-22 广州漫瑞生物信息技术有限公司 一种检测细胞游离肿瘤基因拷贝数变异的系统和方法
GB201811408D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
KR102325731B1 (ko) * 2020-01-15 2021-11-15 주식회사 베르티스 암의 진단용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4937138B2 (ja) * 2005-01-05 2012-05-23 エフ−シュタール・ビオテヒノロギシェ・フォルシュングス−ウント・エントヴィックルングスゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 相補性決定領域とは異なる分子の領域に設計された結合性を持つ合成免疫グロブリンドメイン
ES2975748T3 (es) * 2007-06-26 2024-07-12 F Star Therapeutics Ltd Presentación de agentes de unión
EP2113255A1 (en) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
WO2010136569A1 (en) * 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
EP2407487A1 (en) * 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody

Also Published As

Publication number Publication date
HK1221746A1 (zh) 2017-06-09
HRP20181566T1 (hr) 2018-11-30
SG11201602605TA (en) 2016-04-28
JP6449308B2 (ja) 2019-01-09
LT3052647T (lt) 2018-10-25
EA201690450A1 (ru) 2016-10-31
EP3052647B1 (en) 2018-07-11
KR20160092992A (ko) 2016-08-05
JP2016533395A (ja) 2016-10-27
IL244510A0 (en) 2016-04-21
GB201317622D0 (en) 2013-11-20
DK3052647T3 (en) 2018-10-22
CN105722997A (zh) 2016-06-29
AU2014330942A1 (en) 2016-05-19
BR112016007348A2 (pt) 2018-01-23
CL2016000777A1 (es) 2017-02-17
WO2015049537A1 (en) 2015-04-09
ES2687783T3 (es) 2018-10-29
EP3052647A1 (en) 2016-08-10
US20160289336A1 (en) 2016-10-06
CA2925186A1 (en) 2015-04-09
MX2016004286A (es) 2017-01-18

Similar Documents

Publication Publication Date Title
PE20160950A1 (es) Biomarcadores de cancer y usos de los mismos
CY1119789T1 (el) Cgrp αντισωματα
DOP2020000032A (es) Proteínas de unión específicas y sus usos
CL2017001328A1 (es) Anticuerpos heterodimericos que unen cd3 y antígenos tumorales
CY1120471T1 (el) Αντισωματα κατα του cd70
AR104809A1 (es) Anticuerpos anti-cd40 y usos de los mismos
CY1121900T1 (el) Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
CY1117695T1 (el) Υψηλης συγγενειας ανθρωπινα αντισωματα κατα της ανθρωπινης αγγειοποιητινης-2
MX2021015971A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
AR106752A1 (es) Proteínas de unión a pd1 / ctla4
AR080873A1 (es) Anticuerpos contra factor de crecimiento epidermico (anti-erbb3 o anti-her3)
NZ725079A (en) Transgene genetic tags and methods of use
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
PE20141546A1 (es) Anticuerpos anti-cd134(ox40) y sus usos de los mismos
AR097102A1 (es) Anticuerpo anti-cxcr4 y conjugados de anticuerpo y fármaco
EA201600252A1 (ru) Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
AR091545A1 (es) Anticuerpos anti-egfr y usos de los mismos
BR112015022978A2 (pt) agente de ligação biespecífico, seu método de produção composição farmacêutica, proteína de fusão, uso, sequência de ácido nucleico, vetor, célula hospedeira, método de matar células tumorais e de inibir o crescimento tumoral
PE20141271A1 (es) Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2
CO6450656A2 (es) Anticuerpos anti-tnf-alfa y sus usos
BR112015021819A2 (pt) Tratamento de câncer utilizando receptor quimérico de antígeno humanizado anti-cd19
UA118354C2 (uk) Антитіло до рецептора колонієстимулювального фактора (кфс-1r)
BR112012028764A2 (pt) anticor-pos antifgfr2

Legal Events

Date Code Title Description
FD Application declared void or lapsed